Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31,926 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.
Pan J, Niu Q, Deng B, Liu S, Wu T, Gao Z, Liu Z, Zhang Y, Qu X, Zhang Y, Liu S, Ling Z, Lin Y, Zhao Y, Song Y, Tan X, Zhang Y, Li Z, Yin Z, Chen B, Yu X, Yan J, Zheng Q, Zhou X, Gao J, Chang AH, Feng X, Tong C. Pan J, et al. Among authors: yu x. Leukemia. 2019 Dec;33(12):2854-2866. doi: 10.1038/s41375-019-0488-7. Epub 2019 May 20. Leukemia. 2019. PMID: 31110217 Clinical Trial.
A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL.
Tan Y, Cai H, Li C, Deng B, Song W, Ling Z, Hu G, Yang Y, Niu P, Meng G, Cheng W, Xu J, Duan J, Wang Z, Yu X, Feng X, Zhou J, Pan J. Tan Y, et al. Among authors: yu x. Blood Cancer J. 2021 Apr 10;11(4):71. doi: 10.1038/s41408-021-00465-9. Blood Cancer J. 2021. PMID: 33839735 Free PMC article. Clinical Trial. No abstract available.
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, Seery S, Zhang Y, Peng S, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Yuan Y, Yan F, Tian Z, Tang K, Zhang J, Chang AH, Feng X. Pan J, et al. Among authors: yu x. J Clin Oncol. 2021 Oct 20;39(30):3340-3351. doi: 10.1200/JCO.21.00389. Epub 2021 Jul 29. J Clin Oncol. 2021. PMID: 34324392 Clinical Trial.
Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL.
Deng B, Pan J, Liu Z, Liu S, Chen Y, Qu X, Zhang Y, Lin Y, Zhang Y, Yu X, Zhang Z, Niu X, Luan R, Ma M, Li X, Liu T, Wu X, Niu H, Chang AH, Tong C. Deng B, et al. Among authors: yu x. Mol Ther Methods Clin Dev. 2021 Oct 27;23:633-643. doi: 10.1016/j.omtm.2021.10.006. eCollection 2021 Dec 10. Mol Ther Methods Clin Dev. 2021. PMID: 34901308 Free PMC article.
31,926 results
You have reached the last available page of results. Please see the User Guide for more information.